Brigatinib (AP26113) Efficacy and Safety in ALK plus NSCLC: Phase 1/2 Trial Results

被引：0
|
作者：
Gettinger, Scott N. [1 ]
Bazhenova, Lyudmila [2 ]
Salgia, Ravi [3 ]
Langer, Corey J. [4 ]
Gold, Kathryn A. [5 ]
Rosell, Rafael [6 ,7 ]
Shaw, Alice [8 ]
Weiss, Glen J. [9 ]
Dorer, David J. [10 ]
Rivera, Victor M. [10 ]
Conlan, Maureen G. [10 ]
Kerstein, David [10 ]
Camidge, Ross [11 ]
机构：
[1] Yale Canc Ctr, New Haven, CT USA
[2] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA
[3] Univ Chicago Med, Chicago, IL USA
[4] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Dexeus Univ Inst, Barcelona, Spain
[7] Catalan Inst Oncol, Barcelona, Spain
[8] Massachusetts Gen Hosp, Boston, MA 02114 USA
[9] Canc Treatment Ctr Amer, Goodyear, AZ USA
[10] Ariad Pharmaceut Inc, Cambridge, MA USA
[11] Univ Colorado, Ctr Canc, Aurora, CO USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
NSCLC; TKI; brigatinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ORAL33.06
引用
收藏
页码：S238 / S239
页数：2
相关论文
共 50 条
  • [21] AP26113, A POTENT ALK INHIBITOR, IS ALSO ACTIVE AGAINST EGFR T790M IN MOUSE MODELS OF NSCLC
    Miret, Juan J.
    Wang, Frank
    Anjum, Rana
    Zhang, Sen
    Keats, Jeffrey
    Cookson, Michelle
    Ning, Yaoyu
    Wardwell, Scott
    Moran, Lauren
    Mohemmad, Qurish
    Wang, Yihan
    Qi, Jiwei
    Squillace, Rachel
    Narasimhan, Narayana
    Dalgarno, David
    Clackson, Tim
    Shakespeare, William
    Rivera, Victor
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S577 - S578
  • [22] Brigatinib vs Crizotinib in patients (pts) with ALK inhibitornaive advanced ALK plus NSCLC from the phase 3 ALTA-1L trial
    Griesinger, F.
    Camidge, D. R.
    Kim, H. R.
    Ahn, M. -J.
    Yang, J. C. -H.
    Han, J. -Y.
    Lee, J. -S.
    Hochmair, M.
    Li, J. Y. -C.
    Chang, G. -C.
    Lee, K. H.
    Gridelli, C.
    Delmonte, A.
    Campelo, Garcia M. R.
    Kim, D. -W.
    Bearz, A.
    Morabito, A.
    Felip, E.
    Califano, R.
    Ghosh, S.
    Spira, A.
    Gettinger, S.
    Tiseo, M.
    Haney, J.
    Kerstein, D.
    Popat, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 75 - 76
  • [23] Brigatinib (BRG) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC): Long-term efficacy and safety results from a phase 1/2 trial
    Bazhenova, A.
    Gettinger, S. N.
    Langer, C. J.
    Salgia, R.
    Gold, K. A.
    Rosell, R.
    Shaw, A. T.
    Weiss, G. J.
    Haney, J.
    Rivera, V. M.
    Kerstein, D.
    Camidge, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [24] Updated results of a first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies
    Camidge, D. R.
    Bazhenova, L.
    Salgia, R.
    Weiss, G. J.
    Langer, C. J.
    Shaw, A. T.
    Narasimhan, N. I.
    Dorer, D. J.
    Zhang, J.
    Gettinger, S. N.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S795 - S795
  • [25] UPDATED RESULTS OF A FIRST-IN-HUMAN DOSE-FINDING STUDY OF THE ALK/EGFR INHIBITOR AP26113 IN PATIENTS WITH ADVANCED MALIGNANCIES
    Camidge, D. Ross
    Bazhenova, Lyudmila
    Salgia, Ravi
    Weiss, Glen J.
    Langer, Corey J.
    Shaw, Alice T.
    Narasimhan, Narayana I.
    Dorer, David J.
    Rivera, Victor M.
    Zhang, Joshua
    Clackson, Tim
    Haluska, Frank G.
    Gettinger, Scott N.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S296 - S297
  • [26] The Dual ALK/EGFR Inhibitor AP26113 Also Potently Inhibits Activated and Gatekeeper Mutant Forms of ROS1
    Anjum, R.
    Zhang, S.
    Squillace, R.
    Clackson, T.
    Garner, A. P.
    Rivera, V. M.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 50 - 50
  • [27] Updated Results from the Phase 3 ALTA-1L Trial of Brigatinib (BRG) vs. Crizotinib (CRZ) in ALK Inhibitor-Naive Advanced ALK plus NSCLC
    Griesinger, Frank
    Camidge, D. Ross
    Kim, Hye Ryun
    Ahn, Myung-Ju
    Yang, James Chih-Hsin
    Han, Ji Youn
    Hochmair, Maximilian
    Lee, Hyeong
    Delmonte, Angelo
    Garcia Compelo, Maria Rosario
    Kim, Dong-Wan
    Felip, Enriqueta
    Califano, Raffaele
    Spire, Alexander
    Gettinger, Scott N.
    Tiseo, Marcello
    Lin, Huamao M.
    Ni, Quanhong
    Zhang, Pingkuan
    Popat, Sanjay
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 232 - 232
  • [28] Brigatinib in Crizotinib-Refractory ALK plus NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial
    Camidge, D. Ross
    Tiseo, Marcello
    Ahn, Myung-Ju
    Reckamp, Karen
    Hansen, Karin
    Kim, Sang-We
    Huber, Rudolf
    West, Howard
    Groen, Harry
    Hochmair, Maximilian
    Leighl, Natasha
    Gettinger, Scott
    Langer, Corey
    Paz-Ares, Luis
    Smit, Egbert
    Kim, Edward
    Reichmann, William
    Clackson, Tim
    Kerstein, David
    Haluska, Frank
    Kim, Dong-Wan
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1167 - S1169
  • [29] Integrated efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK plus NSCLC in the ALTA-1L and J-ALTA studies
    Camidge, D. Ross
    Sugawara, Shunichi
    Kondo, Masashi
    Kim, Hye Ryun
    Ahn, Myung-Ju
    Yang, James Chih-Hsin
    Han, Ji-Youn
    Hochmair, Maximilian J.
    Lee, Ki Hyeong
    Delmonte, Angelo
    Kudou, Kentarou
    Asato, Takayuki
    Liu, Yuyin
    Vranceanu, Florin
    Fram, Robert J.
    Ohe, Yuichiro
    Popat, Sanjay
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [30] Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma
    Ceccon, M.
    Mologni, L.
    Giudici, G.
    Piazza, R.
    Pirola, A.
    Fontana, D.
    Gambacorti-Passerini, C.
    MOLECULAR CANCER RESEARCH, 2015, 13 (04) : 775 - 783
12345